The Elton John AIDS Foundation has announced that GRAMMY® Award nominated popstar and Midwest Princess Chappell Roan will ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication associated with bone marrow transplant, as well as a novel HIV drug that only ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 21,980,000 ...

Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.

Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% ...